Bruker Corporation
BRKR
株式のランク
#2331
Bruker Corporation stands as a prominent global developer, manufacturer, and... Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
株価
$55.38
最終同期: 2026-10-19
時価総額
$8.44B
変化（1日）
1.05%
変化（1年）
45.30%
国
US
取引 Bruker Corporation (BRKR)
カテゴリー
Healthcare
Bruker Corporation（BRKR）の利益
Jun 2026 時点の利益 TTM: $-28.10M
Bruker Corporation の最新の財務報告によると、同社の現在の利益は $-28.10M です。2024 年には $205.20M の利益を上げ、これは 2023 年の利益 $546.20M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Bruker Corporation の利益の推移（2000 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $-28.10M | -195.90% |
| 2025 | $29.30M | -85.72% |
| 2024 | $205.20M | -62.43% |
| 2023 | $546.20M | 31.65% |
| 2022 | $414.90M | 5.41% |
| 2021 | $393.60M | 74.31% |
| 2020 | $225.80M | -19.47% |
| 2019 | $280.40M | 14.59% |
| 2018 | $244.70M | 23.71% |
| 2017 | $197.80M | 11.37% |
| 2016 | $177.60M | 38.75% |
| 2015 | $128.00M | 26.36% |
| 2014 | $101.30M | -18.70% |
| 2013 | $124.60M | -9.91% |
| 2012 | $138.30M | -4.95% |
| 2011 | $145.50M | -3.06% |
| 2010 | $150.10M | 16.27% |
| 2009 | $129.10M | 38.52% |
| 2008 | $93.20M | 91.72% |
| 2007 | $48.61M | 41.23% |
| 2006 | $34.42M | 188.06% |
| 2005 | $11.95M | -344.01% |
| 2004 | $-4.90M | -37.46% |
| 2003 | $-7.83M | 89.27% |
| 2002 | $-4.14M | -168.88% |
| 2001 | $6.01M | 158.88% |
| 2000 | $2.32M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $7.51B | -26,829.54% |
US
|
|
| $5.56B | -19,897.15% |
IE
|
|
| $5.15B | -18,420.28% |
US
|
|
| $3.86B | -13,840.21% |
US
|
|
| - | - |
DE
|
